Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Breakthrough Therapy Designation by the FDA for the Treatment of PROC

Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio ...

How Sydney Jo turned her Notes app drafts into TikTok’s most relatable friend group

You might know Sydney Jo, aka @ thatgirlsydjo, for her TikTok project, The Group Chat, which she wrote on her Notes app ...
Education WeekOpinion

Yes, Small-Group Reading Instruction Works. But Use It Wisely

Small-group instruction has been a popular component of K-3 literacy education for many years. However, there are inevitable ...
Psychology TodayOpinion

AI in the Therapy Room

When a therapist used AI without consent, trust was broken. Here’s what clients deserve to know—and what ethical AI use in ...
Psychology Today

When to Prioritize Solitude—and When to Participate

How do we balance our individual—selfish, dare I say—needs with the collective? A simple equation offers clarity for one of ...

Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

The CUTX-101 NDA was initially granted Priority Review by the FDA and is supported by positive topline clinical efficacy results for CUTX-101, demonstrating significant improvement in overall survival ...

Sentynl Therapeutics Announces FDA Acceptance of CUTX-101 NDA Resubmission

Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. ("Zydus Group"), today announced that the U.S. Food and Drug Administration (FDA ...